GLP-1 Medications May Reduce Risk of Obesity-Related Cancers, Study Finds
GLP-1 drugs linked to lower cancer risk
New research suggests that GLP-1 medications are associated with a lower risk of developing several obesity-related cancers compared to insulin and sulfonylureas, NewsNation reported.
- Patients starting GLP-1 drugs showed lower rates of obesity-related cancers than those starting insulin or sulfonylureas.
- The observational study, published in JAMA Network Open, tracked patients over three- and five-year periods.
- Researchers caution that the findings show an association rather than direct prevention, noting the drugs are not approved solely for cancer reduction.
Study design and patient populations
Researchers examined whether medications such as Ozempic, Wegovy, Mounjaro, and Trulicity correlate with reduced cancer incidence in adults with Type 2 diabetes. The study compared patients who initiated GLP-1 therapy against those prescribed alternative diabetes regimens over distinct three- and five-year follow-up windows. Lower cancer rates appeared prominently among adults presenting with less severe diabetes manifestations.
Additional research from database analyses expanded these observations into specific patient subgroups. Investigators utilizing the TriNetX network identified more than 69,000 individuals with inflammatory bowel disease and over 37,000 people managing both inflammatory bowel disease and type 2 diabetes, as detailed in reports regarding the study abstract presented at the 2025 ASCO Annual Meeting.
Within those cohorts, GLP-1 receptor agonist use linked to a 51% decrease in the odds of developing colorectal cancer for patients with inflammatory bowel disease.
For individuals dealing with both inflammatory bowel disease and Type 2 diabetes, GLP-1 utilization associated with a 46% decrease in colorectal cancer odds. An investigator from Case Western Reserve University noted that the results suggest these drugs could potentially offer benefits beyond glucose control and weight loss. A specialist from the Department of Medicine at Case Western Reserve University described the findings as promising data supporting further evaluation in high-risk populations.
GLP-1 medications may possess intrinsic cancer-protective properties
According to an American Cancer Society report, excess weight stands as a recognized risk factor for at least 13 distinct types of cancer. However, analysts point out that weight reduction alone may not drive the entire protective signal. The American Cancer Society report indicates that GLP-1 medications may possess intrinsic cancer-protective properties through limiting cancer cell proliferation, suppressing inflammation, and enhancing cancer detection capabilities.
The underlying longitudinal research received financial support from the National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases under grant R01DK133465. The funding body played no operational role in study design, data collection, analysis, manuscript preparation, or the ultimate decision to publish. An abstract detailing these findings previously appeared at the 2025 ASCO Annual Meeting held in Chicago on June 2, 2025.
Current clinical uncertainties
Despite the observed correlations, the American Cancer Society stresses that individuals should not take GLP-1 medications solely for cancer risk reduction since regulatory bodies have not approved them for that specific indication. Researchers emphasize that the investigation identifies an association rather than proving direct causation. Prospective, forward-looking studies remain necessary to confirm these epidemiological patterns.
Meanwhile, questions persist regarding specific adverse reactions associated with the drug class. GLP-1 users have reported painful skin side effects that doctors are actively working to understand and characterize.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.